Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS

G. L. Mancardi, R. Saccardi, M. Filippi, F. Gualandi, A. Murialdo, M. Inglese, M. G. Marrosu, G. Meucci, L. Massacesi, A. Lugaresi, F. Pagliai, M. P. Sormani, F. Sardanelli, A. Marmont

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Background: Autologous hematopoietic stem cell transplantation (ASCT) has been recently utilized with encouraging results in patients with poorly controlled MS. Objective: To determine in severe cases of MS the effect of ASCT on gadolinium (Gd)-enhanced MRI and to obtain information on clinical course and safety. Methods: In a cooperative study, 10 patients with rapidly evolving secondary progressive MS were transplanted, after BEAM conditioning regimen (carmustine, etoposide, cytosine-arabinoside, and melphalan), with unmanipulated autologous peripheral blood SC mobilized with high-dose cyclophosphamide (CY; 4 g/m2) and granulocyte-colony-stimulating factor. Triple-dose Gd-enhanced scans were performed monthly for a pretreatment period of 3 months and compared with serial monthly Gd-enhanced MRI for the following 6 months and then once every 3 months. Results: The median follow-up is now 15 months (range 4 to 30 months). The number of Gd-enhancing lesions decreased immediately after mobilization with CY and finally dropped to zero in all cases after the conditioning regimen. The number of new T2-weighted positive lesions paralleled data obtained for Gd-enhanced MRI. Clinically, patients improved slightly or remained stable. Conclusion: These results demonstrate that the therapeutic sequence CY-BEAM-ASCT has the capacity to completely suppress MR-enhancing activity, an effect that is sustained with time. The final impact of this procedure on disease course remains to be established.

Original languageEnglish
Pages (from-to)62-68
Number of pages7
JournalNeurology
Volume57
Issue number1
Publication statusPublished - Jul 10 2001

Fingerprint

Hematopoietic Stem Cell Transplantation
Gadolinium
Carmustine
Melphalan
Cytarabine
Granulocyte Colony-Stimulating Factor
Etoposide
Cyclophosphamide
Safety

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Mancardi, G. L., Saccardi, R., Filippi, M., Gualandi, F., Murialdo, A., Inglese, M., ... Marmont, A. (2001). Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology, 57(1), 62-68.

Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. / Mancardi, G. L.; Saccardi, R.; Filippi, M.; Gualandi, F.; Murialdo, A.; Inglese, M.; Marrosu, M. G.; Meucci, G.; Massacesi, L.; Lugaresi, A.; Pagliai, F.; Sormani, M. P.; Sardanelli, F.; Marmont, A.

In: Neurology, Vol. 57, No. 1, 10.07.2001, p. 62-68.

Research output: Contribution to journalArticle

Mancardi, GL, Saccardi, R, Filippi, M, Gualandi, F, Murialdo, A, Inglese, M, Marrosu, MG, Meucci, G, Massacesi, L, Lugaresi, A, Pagliai, F, Sormani, MP, Sardanelli, F & Marmont, A 2001, 'Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS', Neurology, vol. 57, no. 1, pp. 62-68.
Mancardi, G. L. ; Saccardi, R. ; Filippi, M. ; Gualandi, F. ; Murialdo, A. ; Inglese, M. ; Marrosu, M. G. ; Meucci, G. ; Massacesi, L. ; Lugaresi, A. ; Pagliai, F. ; Sormani, M. P. ; Sardanelli, F. ; Marmont, A. / Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. In: Neurology. 2001 ; Vol. 57, No. 1. pp. 62-68.
@article{3a6ecc3e4df949599534d5a5a69ba9b6,
title = "Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS",
abstract = "Background: Autologous hematopoietic stem cell transplantation (ASCT) has been recently utilized with encouraging results in patients with poorly controlled MS. Objective: To determine in severe cases of MS the effect of ASCT on gadolinium (Gd)-enhanced MRI and to obtain information on clinical course and safety. Methods: In a cooperative study, 10 patients with rapidly evolving secondary progressive MS were transplanted, after BEAM conditioning regimen (carmustine, etoposide, cytosine-arabinoside, and melphalan), with unmanipulated autologous peripheral blood SC mobilized with high-dose cyclophosphamide (CY; 4 g/m2) and granulocyte-colony-stimulating factor. Triple-dose Gd-enhanced scans were performed monthly for a pretreatment period of 3 months and compared with serial monthly Gd-enhanced MRI for the following 6 months and then once every 3 months. Results: The median follow-up is now 15 months (range 4 to 30 months). The number of Gd-enhancing lesions decreased immediately after mobilization with CY and finally dropped to zero in all cases after the conditioning regimen. The number of new T2-weighted positive lesions paralleled data obtained for Gd-enhanced MRI. Clinically, patients improved slightly or remained stable. Conclusion: These results demonstrate that the therapeutic sequence CY-BEAM-ASCT has the capacity to completely suppress MR-enhancing activity, an effect that is sustained with time. The final impact of this procedure on disease course remains to be established.",
author = "Mancardi, {G. L.} and R. Saccardi and M. Filippi and F. Gualandi and A. Murialdo and M. Inglese and Marrosu, {M. G.} and G. Meucci and L. Massacesi and A. Lugaresi and F. Pagliai and Sormani, {M. P.} and F. Sardanelli and A. Marmont",
year = "2001",
month = "7",
day = "10",
language = "English",
volume = "57",
pages = "62--68",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS

AU - Mancardi, G. L.

AU - Saccardi, R.

AU - Filippi, M.

AU - Gualandi, F.

AU - Murialdo, A.

AU - Inglese, M.

AU - Marrosu, M. G.

AU - Meucci, G.

AU - Massacesi, L.

AU - Lugaresi, A.

AU - Pagliai, F.

AU - Sormani, M. P.

AU - Sardanelli, F.

AU - Marmont, A.

PY - 2001/7/10

Y1 - 2001/7/10

N2 - Background: Autologous hematopoietic stem cell transplantation (ASCT) has been recently utilized with encouraging results in patients with poorly controlled MS. Objective: To determine in severe cases of MS the effect of ASCT on gadolinium (Gd)-enhanced MRI and to obtain information on clinical course and safety. Methods: In a cooperative study, 10 patients with rapidly evolving secondary progressive MS were transplanted, after BEAM conditioning regimen (carmustine, etoposide, cytosine-arabinoside, and melphalan), with unmanipulated autologous peripheral blood SC mobilized with high-dose cyclophosphamide (CY; 4 g/m2) and granulocyte-colony-stimulating factor. Triple-dose Gd-enhanced scans were performed monthly for a pretreatment period of 3 months and compared with serial monthly Gd-enhanced MRI for the following 6 months and then once every 3 months. Results: The median follow-up is now 15 months (range 4 to 30 months). The number of Gd-enhancing lesions decreased immediately after mobilization with CY and finally dropped to zero in all cases after the conditioning regimen. The number of new T2-weighted positive lesions paralleled data obtained for Gd-enhanced MRI. Clinically, patients improved slightly or remained stable. Conclusion: These results demonstrate that the therapeutic sequence CY-BEAM-ASCT has the capacity to completely suppress MR-enhancing activity, an effect that is sustained with time. The final impact of this procedure on disease course remains to be established.

AB - Background: Autologous hematopoietic stem cell transplantation (ASCT) has been recently utilized with encouraging results in patients with poorly controlled MS. Objective: To determine in severe cases of MS the effect of ASCT on gadolinium (Gd)-enhanced MRI and to obtain information on clinical course and safety. Methods: In a cooperative study, 10 patients with rapidly evolving secondary progressive MS were transplanted, after BEAM conditioning regimen (carmustine, etoposide, cytosine-arabinoside, and melphalan), with unmanipulated autologous peripheral blood SC mobilized with high-dose cyclophosphamide (CY; 4 g/m2) and granulocyte-colony-stimulating factor. Triple-dose Gd-enhanced scans were performed monthly for a pretreatment period of 3 months and compared with serial monthly Gd-enhanced MRI for the following 6 months and then once every 3 months. Results: The median follow-up is now 15 months (range 4 to 30 months). The number of Gd-enhancing lesions decreased immediately after mobilization with CY and finally dropped to zero in all cases after the conditioning regimen. The number of new T2-weighted positive lesions paralleled data obtained for Gd-enhanced MRI. Clinically, patients improved slightly or remained stable. Conclusion: These results demonstrate that the therapeutic sequence CY-BEAM-ASCT has the capacity to completely suppress MR-enhancing activity, an effect that is sustained with time. The final impact of this procedure on disease course remains to be established.

UR - http://www.scopus.com/inward/record.url?scp=0035838312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035838312&partnerID=8YFLogxK

M3 - Article

C2 - 11445629

AN - SCOPUS:0035838312

VL - 57

SP - 62

EP - 68

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 1

ER -